Clinical features and risk factors of immune-mediated liver injury in non-small cell lung cancer patients treated with immune checkpoint inhibitors
PurposeThis study investigated the clinical features, risk factors, and recurrence of immune-mediated liver injury (IMLI) in non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs).MethodsA retrospective cohort of 274 NSCLC patients receiving ICIs was analyzed. B...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1575376/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849389527246831616 |
|---|---|
| author | Ling Yang Chao Zhuo Chonghuan Li Yujing Liu Xinyi Liu Yibin Huang Bingbing Wu Jiawei Su |
| author_facet | Ling Yang Chao Zhuo Chonghuan Li Yujing Liu Xinyi Liu Yibin Huang Bingbing Wu Jiawei Su |
| author_sort | Ling Yang |
| collection | DOAJ |
| description | PurposeThis study investigated the clinical features, risk factors, and recurrence of immune-mediated liver injury (IMLI) in non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs).MethodsA retrospective cohort of 274 NSCLC patients receiving ICIs was analyzed. Baseline inflammatory markers, including white blood cell count (WBC), albumin levels, and prognostic nutritional index (PNI), were assessed for their association with IMLI. Risk factors were identified using logistic regression, and recurrence outcomes were analyzed.ResultsIMLI incidence was 35.4%, with 15.5% of cases classified as grade 3-4. WBC ≤11.0×109/L (P<0.001) and albumin ≥35 g/L (P<0.001) were independent predictors of IMLI. Among patients with IMLI, 28.9% experienced recurrence, with 17.9% classified as grade 3-4. Recurrence risk was not significantly higher than the initial onset (P=0.21).ConclusionLow baseline inflammatory status predicts IMLI in NSCLC patients undergoing ICI therapy. Monitoring baseline inflammatory markers can guide risk stratification, and re-challenging ICIs in selected patients appears feasible without significantly increasing recurrence risk. |
| format | Article |
| id | doaj-art-4f555bb2a0e047e2a3ecbad5a994e1e0 |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-4f555bb2a0e047e2a3ecbad5a994e1e02025-08-20T03:41:57ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-08-011510.3389/fonc.2025.15753761575376Clinical features and risk factors of immune-mediated liver injury in non-small cell lung cancer patients treated with immune checkpoint inhibitorsLing Yang0Chao Zhuo1Chonghuan Li2Yujing Liu3Xinyi Liu4Yibin Huang5Bingbing Wu6Jiawei Su7Department of Infectious Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, ChinaDepartment of Infectious Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, ChinaDepartment of Clinical Medicine, Guangzhou Medical University, Guangzhou, ChinaDepartment of Clinical Medicine, Guangzhou Medical University, Guangzhou, ChinaDepartment of Clinical Medicine, Guangzhou Medical University, Guangzhou, ChinaDepartment of Clinical Medicine, Guangzhou Medical University, Guangzhou, ChinaDepartment of Clinical Medicine, Guangzhou Medical University, Guangzhou, ChinaDepartment of Clinical Medicine, Guangzhou Medical University, Guangzhou, ChinaPurposeThis study investigated the clinical features, risk factors, and recurrence of immune-mediated liver injury (IMLI) in non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs).MethodsA retrospective cohort of 274 NSCLC patients receiving ICIs was analyzed. Baseline inflammatory markers, including white blood cell count (WBC), albumin levels, and prognostic nutritional index (PNI), were assessed for their association with IMLI. Risk factors were identified using logistic regression, and recurrence outcomes were analyzed.ResultsIMLI incidence was 35.4%, with 15.5% of cases classified as grade 3-4. WBC ≤11.0×109/L (P<0.001) and albumin ≥35 g/L (P<0.001) were independent predictors of IMLI. Among patients with IMLI, 28.9% experienced recurrence, with 17.9% classified as grade 3-4. Recurrence risk was not significantly higher than the initial onset (P=0.21).ConclusionLow baseline inflammatory status predicts IMLI in NSCLC patients undergoing ICI therapy. Monitoring baseline inflammatory markers can guide risk stratification, and re-challenging ICIs in selected patients appears feasible without significantly increasing recurrence risk.https://www.frontiersin.org/articles/10.3389/fonc.2025.1575376/fullimmune checkpoint inhibitorsimmune-mediated liver injuryimmune-related adverse eventsclinical featuresinflammatory biomarkers |
| spellingShingle | Ling Yang Chao Zhuo Chonghuan Li Yujing Liu Xinyi Liu Yibin Huang Bingbing Wu Jiawei Su Clinical features and risk factors of immune-mediated liver injury in non-small cell lung cancer patients treated with immune checkpoint inhibitors Frontiers in Oncology immune checkpoint inhibitors immune-mediated liver injury immune-related adverse events clinical features inflammatory biomarkers |
| title | Clinical features and risk factors of immune-mediated liver injury in non-small cell lung cancer patients treated with immune checkpoint inhibitors |
| title_full | Clinical features and risk factors of immune-mediated liver injury in non-small cell lung cancer patients treated with immune checkpoint inhibitors |
| title_fullStr | Clinical features and risk factors of immune-mediated liver injury in non-small cell lung cancer patients treated with immune checkpoint inhibitors |
| title_full_unstemmed | Clinical features and risk factors of immune-mediated liver injury in non-small cell lung cancer patients treated with immune checkpoint inhibitors |
| title_short | Clinical features and risk factors of immune-mediated liver injury in non-small cell lung cancer patients treated with immune checkpoint inhibitors |
| title_sort | clinical features and risk factors of immune mediated liver injury in non small cell lung cancer patients treated with immune checkpoint inhibitors |
| topic | immune checkpoint inhibitors immune-mediated liver injury immune-related adverse events clinical features inflammatory biomarkers |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1575376/full |
| work_keys_str_mv | AT lingyang clinicalfeaturesandriskfactorsofimmunemediatedliverinjuryinnonsmallcelllungcancerpatientstreatedwithimmunecheckpointinhibitors AT chaozhuo clinicalfeaturesandriskfactorsofimmunemediatedliverinjuryinnonsmallcelllungcancerpatientstreatedwithimmunecheckpointinhibitors AT chonghuanli clinicalfeaturesandriskfactorsofimmunemediatedliverinjuryinnonsmallcelllungcancerpatientstreatedwithimmunecheckpointinhibitors AT yujingliu clinicalfeaturesandriskfactorsofimmunemediatedliverinjuryinnonsmallcelllungcancerpatientstreatedwithimmunecheckpointinhibitors AT xinyiliu clinicalfeaturesandriskfactorsofimmunemediatedliverinjuryinnonsmallcelllungcancerpatientstreatedwithimmunecheckpointinhibitors AT yibinhuang clinicalfeaturesandriskfactorsofimmunemediatedliverinjuryinnonsmallcelllungcancerpatientstreatedwithimmunecheckpointinhibitors AT bingbingwu clinicalfeaturesandriskfactorsofimmunemediatedliverinjuryinnonsmallcelllungcancerpatientstreatedwithimmunecheckpointinhibitors AT jiaweisu clinicalfeaturesandriskfactorsofimmunemediatedliverinjuryinnonsmallcelllungcancerpatientstreatedwithimmunecheckpointinhibitors |